MicroRNA and renal fibrosis in autosomal dominant polycystic kidney disease: a longitudinal study.
Autosomal dominant polycystic kidney disease
Plasma aldosterone
Subclinical atherosclerosis parameters
Total fibrotic volume
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
05 Jul 2024
05 Jul 2024
Historique:
received:
10
11
2023
accepted:
26
04
2024
medline:
6
7
2024
pubmed:
6
7
2024
entrez:
5
7
2024
Statut:
aheadofprint
Résumé
Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary kidney disorder that may progress to kidney failure, accounting for 5-10% of all patients with end-stage kidney disease (ESKD). Clinical data, as well as molecular genetics and advanced imaging techniques have provided surrogate prognostic biomarkers to predict rapid decline in kidney function, nonetheless enhanced tools for assessing prognosis for ADPKD are still needed. The aim of this study was to analyze specific microRNAs involved in the pathogenesis of ADPKD and in the development of renal fibrosis, evaluating their potential role as predictors of renal function loss. We evaluated kidney function by estimated glomerular filtration rate (eGFR) in 32 ADPKD patients in different stages of kidney disease at T0 and after a 24-month follow up (T1). Patients were divided into two groups: Rapid disease progression ([RP], n 15) and Non-rapid disease progression ([NRP], n 17), according to the Mayo Clinic classification criteria. At T0, ADPKD patients underwent plasma sampling for quantitative analysis of h-miR-17-5p, h-miR-21-5p and h-miR-199a-5p microRNA expression, using the quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) method and a 3 T magnetic resonance imaging (MRI), using an advanced MRI imaging protocol, for the quantification of total kidney volume (TKV), total perfusion volume (TPV) and total fibrotic volume (TFV). The expression of h-miR17-5p was higher (p < 0.05) in ADPKD patients with rapid disease progression. h-miR-17-5p, h-miR-21-5p and h-mir-199-5p showed a positive and significant correlation with the eGFR slope (mL/min/1.73 m The microRNAs we studied were associated with fibrosis and renal damage, suggesting their possible role as biomarkers able to identify ADPKD patients at high risk of disease progression regardless of the degree of kidney function, and therefore suitable for medical therapy, and may help uncovering new molecular mechanisms underlying cystogenesis.
Sections du résumé
BACKGROUND
BACKGROUND
Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary kidney disorder that may progress to kidney failure, accounting for 5-10% of all patients with end-stage kidney disease (ESKD). Clinical data, as well as molecular genetics and advanced imaging techniques have provided surrogate prognostic biomarkers to predict rapid decline in kidney function, nonetheless enhanced tools for assessing prognosis for ADPKD are still needed. The aim of this study was to analyze specific microRNAs involved in the pathogenesis of ADPKD and in the development of renal fibrosis, evaluating their potential role as predictors of renal function loss.
METHODS
METHODS
We evaluated kidney function by estimated glomerular filtration rate (eGFR) in 32 ADPKD patients in different stages of kidney disease at T0 and after a 24-month follow up (T1). Patients were divided into two groups: Rapid disease progression ([RP], n 15) and Non-rapid disease progression ([NRP], n 17), according to the Mayo Clinic classification criteria. At T0, ADPKD patients underwent plasma sampling for quantitative analysis of h-miR-17-5p, h-miR-21-5p and h-miR-199a-5p microRNA expression, using the quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) method and a 3 T magnetic resonance imaging (MRI), using an advanced MRI imaging protocol, for the quantification of total kidney volume (TKV), total perfusion volume (TPV) and total fibrotic volume (TFV).
RESULTS
RESULTS
The expression of h-miR17-5p was higher (p < 0.05) in ADPKD patients with rapid disease progression. h-miR-17-5p, h-miR-21-5p and h-mir-199-5p showed a positive and significant correlation with the eGFR slope (mL/min/1.73 m
CONCLUSIONS
CONCLUSIONS
The microRNAs we studied were associated with fibrosis and renal damage, suggesting their possible role as biomarkers able to identify ADPKD patients at high risk of disease progression regardless of the degree of kidney function, and therefore suitable for medical therapy, and may help uncovering new molecular mechanisms underlying cystogenesis.
Identifiants
pubmed: 38969871
doi: 10.1007/s40620-024-01965-0
pii: 10.1007/s40620-024-01965-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Torres VE, Harris PC, Pirson Y (2007) Autosomal dominant polycystic kidney disease. Lancet 369:1287–1301
doi: 10.1016/S0140-6736(07)60601-1
pubmed: 17434405
Rossetti S, Consugar MB, Chapman AB et al (2007) Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am SocNephrol 18:2143–2160
Torres VE, Harris PC (2014) Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 25(1):18–32
doi: 10.1681/ASN.2013040398
pubmed: 24335972
Fain PR et al (2005) Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int 67:1256–1267
doi: 10.1111/j.1523-1755.2005.00203.x
pubmed: 15780078
Hopp K et al (2012) Functional polycystin-1 dosage govern: autosomal dominant polycystic kidney disease severity. J Clin Invest 122:4257–4273
doi: 10.1172/JCI64313
pubmed: 23064367
pmcid: 3484456
Cornec-Le Gall E et al (2013) Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24:1006–1013
doi: 10.1681/ASN.2012070650
pubmed: 23431072
pmcid: 3665389
Rowe I, Boletta A (2014) Defective metabolism in polycystic kidney disease: potential for therapy and open questions. Nephrol Dial Transplant 29(8):1480–1486
doi: 10.1093/ndt/gft521
pubmed: 24459136
Odedra D, Sabongui S, Khalili K, Schieda N, Pei Y, Krishna S (2023) Autosomal dominant polycystic kidney disease: role of imaging in diagnosis and management. Radiographics 43(1):e220126
doi: 10.1148/rg.220126
pubmed: 36459494
Antiga L, Piccinelli M, Fasolini G, Ene-Iordache B, Ondei P, Bruno S, Remuzzi G, Remuzzi A (2006) Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin J Am Soc Nephrol 1(4):754–760
doi: 10.2215/CJN.02251205
pubmed: 17699283
Cyclic WDP (2011) Cyclic AMP-mediated cyst expansion. Biochem Biophys Acta 1812(10):1291–1300
Chapman AB, Guay-Woodford LM, Grantham JJ et al (2003) Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64(3):1035–1045
doi: 10.1046/j.1523-1755.2003.00185.x
pubmed: 12911554
Irazabal MV et al (2015) Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26(1):160–172
doi: 10.1681/ASN.2013101138
pubmed: 24904092
Lai S, Mastroluca D, Letizia C, Petramala L, Perrotta AM, DiGaeta A, Ferrigno L, Ciccariello M, D’Angelo AR, Panebianco V (2018) Magnetic resonance imaging 3T and total fibrotic volume in autosomal dominant polycystic kidney disease. Intern Med J 48(12):1505–1513. https://doi.org/10.1111/imj.14039 . (PMID: 30043487)
doi: 10.1111/imj.14039
pubmed: 30043487
Lai S, Perrotta AM, Panebianco V, Mazzaferro S, Menè P, Pellicano C, Tinti F, Muscaritoli M, Cianci R, Gigante A (2023) Parasympathetic activity and total fibrotic kidney in autosomal-dominant polycystic kidney disease patients: a pilot study. Int Urol Nephrol 55(12):3153–3158. https://doi.org/10.1007/s11255-023-03551-y . (Epub 2023 Apr 12. PMID: 37043156; PMCID: PMC10611859)
doi: 10.1007/s11255-023-03551-y
pubmed: 37043156
pmcid: 10611859
Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP (2008) The impact of microRNAs on protein output. Nat Cell Biol 455:64–71
Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12:861–874
doi: 10.1038/nrg3074
pubmed: 22094949
Li JY, Yong TY, Michael MZ, Gleadle JM (2010) Review: the role of microRNAs in kidney disease. Rev Nephrol (Carlton) 15(6):599–608
doi: 10.1111/j.1440-1797.2010.01363.x
Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D (2009) Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 20(1):205–212
doi: 10.1681/ASN.2008050507
pubmed: 18945943
pmcid: 2615723
Persu A et al (2004) Comparison between siblings and twins supports a role for modifier genes in ADPKD. Kidney Int 66:2132–2136
doi: 10.1111/j.1523-1755.2004.66003.x
pubmed: 15569302
Pandey P, Brors B, Srivastava PK, Bott A, Boehn SNE, Groene H-J, Gretz N (2008) Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease. BMC Genomics 23(9):624
doi: 10.1186/1471-2164-9-624
Zhou JX, Li X (2021) Non-coding RNAs in hereditary kidney disorders. Review Int J Mol Sci. 22(6):3014
doi: 10.3390/ijms22063014
pubmed: 33809516
Sun L, Zhu J, Ming Wu, Sun H, Zhou C, Lili Fu, Chenggang Xu, Mei C (2015) Inhibition of MiR-199a-5p reduced cell proliferation in autosomal dominant polycystic kidney disease through targeting CDKN1C. Med Sci Monit 15(21):195–200
Lakhia R, Hajarnis S, Williams D, Aboudehen K, Yheskel M, Xing III C, Hatley ME, Torres VE, Wallace DP, Patel V (2016) MicroRNA-21 aggravates cyst growth in a model of polycystic kidney disease. J Am Soc Nephrol 27(8):2319–2330
doi: 10.1681/ASN.2015060634
pubmed: 26677864
Hajarnis S, Lakhia R, Yheskel M, Williams D, Sorourian M, Liu X, Aboudehen K, Zhang S, Kersjes K, Galasso R, Li J, Kaimal V, Lockton S, Davis S, Flaten A, Johnson JA, Holland WL, Kusminski CM, Scherer PE, Harris PC, Trudel M, Wallace DP, Igarashi P, Lee EC, Androsavich JR, Patel V (2017) MicroRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Nat Commun 8:14395
doi: 10.1038/ncomms14395
pubmed: 28205547
pmcid: 5316862